Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications.
OBJECTIVE
Osteoporosis is increasingly common worldwide and there is a growing concern that the long-term use of antipsychotic medications increases the risk of this disorder. In this review, we consider whether antipsychotics may contribute to the development of osteoporosis through reductions in bone mineral density, discuss the possible mechanisms involved and consider the clinical implications of such a relationship.


METHODS
We searched the literature for studies in this area published between 1966 and 2010 using the Medline and PubMed databases, supplemented by hand searches of retrieved reports.


RESULTS
The available data indicate that statistically significant reductions in bone mineral density are frequently seen in patients prescribed with antipsychotic medications and suggest that there is a higher incidence of clinically significant reductions compared with the normal population.


CONCLUSIONS
Clinicians should be aware for the potential negative effects of antipsychotic medications on bone mineral density, particularly in patients with additional risk factors for osteoporosis. Recommendations regarding routine monitoring of bone mineral density for patients prescribed antipsychotic medications cannot be made on the basis of existing evidence, and more research is required.
South London and Maudsley NHS Foundation Trust, The Maudsley Hospital, Denmark Hill, London, SE5 8AZ, UK. Matthieu.Crews@slam.nhs.uk
Matthieu P K
MP
Crews
Oliver D
OD
Howes
D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects*; D016903:Drug Monitoring; D006801:Humans; D010024:Osteoporosis / Q000453:epidemiology / Q000209:etiology*; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy
D014150:Antipsychotic Agents